Accessibility Menu
Envoy Medical logo

Envoy Medical(NASDAQ) COCH

Current Price$0.69
Market Cap$53.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-93%
5 Year-93%
1 Year-57%
1 Month+5%
Envoy Medical last closing stock price
MetricPriceDate
Last closeUSD 0.692026-07-22
Envoy Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.23%USD 0.722026-07-15
1 month+4.95%USD 0.662026-06-22
3 month+0.42%USD 0.692026-04-23
Year to date+4.81%USD 0.662025-12-31
1 year-56.96%USD 1.612025-07-22
3 year-93.32%USD 10.372023-07-21
5 year-92.81%USD 9.642021-07-23
Since inception-92.9%USD 9.762021-04-29

Envoy Medical Financials at a Glance

Market Cap

$53.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$234.00K

Net Income (TTM)

-$23.11M

EPS (TTM)

-$1.03

P/E Ratio

-0.67

Dividend

$0.00

Beta (Volatility)

0.20 (Low)

Price

$0.69

Volume

0

Open

$0.69

Previous Close

$0.69

Daily Range

$0.68 - $0.70

52-Week Range

$0.36 - $1.89

Estimated Earnings Date

Jul 30, 2026

COCH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Envoy Medical

Envoy Medical makes hearing devices for people with hearing loss. Its implants work fully inside the ear, helping users hear without visible parts. These products aim to help adults who do not benefit from regular hearing aids.

Products and Services

  • Esteem FI-AMEI: Fully implanted middle ear device for moderate to severe hearing loss; nearly all current revenue.
  • Acclaim CI: Fully implanted cochlear implant for severe hearing loss; in clinical trials, no revenue yet.
  • Bone Conduction Devices: Devices for people with certain types of hearing loss; small part of portfolio.
  • Hearing Aids: Traditional devices for mild to moderate hearing loss; minor revenue contribution.
  • Patient Support Services: Ongoing care and replacement parts for existing implant users.

Growth and Expansion

  • Launched Esteem FI-AMEI in the U.S. market; date not specified.
  • Began pivotal clinical trials for Acclaim CI in 2025, enrolling 56 patients by March 2026.
  • Raised $27.7 million in a public offering in February 2026 to fund clinical trials and operations.
  • Plans to seek FDA approval for Acclaim CI by late 2027 or early 2028.
  • Intends to pursue CE Mark for European entry after U.S. approval.

What Makes Envoy Medical Stand Out

Envoy Medical focuses on fully implanted hearing devices, removing the need for visible external parts. Its sensor technology uses the ear’s natural structure to capture sound. The company holds a large patent portfolio, supporting its unique approach in the hearing device market.

Five Things You Need to Know

  • Net revenues were $241,000 in FY 2025, up 7.1% from FY 2024.
  • Net loss was $23.8 million in FY 2025, up 14.2% year-over-year.
  • R&D expenses rose 22.7% to $12.5 million in FY 2025.
  • Cash was $3.7 million at December 31, 2025, down from $5.5 million in 2024.

Bottom Line

Envoy Medical has focused on innovation in fully implanted hearing devices. The company faces ongoing financial challenges as it seeks regulatory approval for new products.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

43

CEO

Brent T. Lucas

Website

www.envoymedical.com

Headquarters

White Bear Lake, MN 55110, US

COCH Financials

Key Financial Metrics (TTM)

Gross Margin

-310.68%

Operating Margin

-9881.20%

Net Income Margin

-9875.64%

Return on Equity

239.44%

Return on Capital

N/A

Return on Assets

-77.49%

Earnings Yield

-1.49%

Dividend Yield

0.00%

Payout Ratio

-8.46%

Stock Overview

Market Cap

$53.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

76.88M

Volume

0

Avg. Volume

391.80K

Financials (TTM)

Gross Profit

-$727.00K

Operating Income

-$23.12M

EBITDA

-$21.70M

Operating Cash Flow

-$20.54M

Capital Expenditure

-$173.00K

Free Cash Flow

-$20.71M

Cash & ST Invst.

$25.25M

Total Debt

$889.00K

Envoy Medical Performance Analysis

Envoy Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 237,000N/A
20232023-12-31USD 316,00033.3%
20242024-12-31USD 225,000-28.8%
20252025-12-31USD 241,0007.1%
Envoy Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3069.6%
Q32025-09-30-46.2%
Q42025-12-3178.6%
Q12026-03-31-48.0%
Envoy Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.5733366.0%
20232023-12-31USD -2.5461.7%
20242024-12-31USD -1.49-41.5%
20252025-12-31USD -1.23-17.2%
Envoy Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-10.3%
Q32025-09-30-9.4%
Q42025-12-3122.9%
Q12026-03-3169.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$39.00K

-15.2%

Gross Profit

-$274.00K

-52.2%

Gross Margin

-7.03%

N/A

Market Cap

$53.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.24M

N/A

Employees

43

N/A

Net Income

-$4.35M

+12.9%

EBITDA

-$4.28M

+3.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$25.25M

+375.4%

Total Debt

$889.00K

-96.3%

Accounts Receivable

$48.00K

+14.3%

Inventory

$1.49M

-10.1%

Long Term Debt

$711.00K

-97.0%

Short Term Debt

$178.00K

+22.8%

Return on Assets

-77.49%

N/A

Return on Invested Capital

-1.31%

N/A

Free Cash Flow

-$6.06M

-62.4%

Operating Cash Flow

-$6.06M

-62.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATHAAthira Pharma, Inc.
$6.75-6.12%
IRIXIRIDEX Corporation
$0.92+0.00%
ADGMAdagio Medical Holdings, Inc.
$0.47+5.66%
CODXCo-Diagnostics, Inc.
$2.28-3.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About COCH

What is the current price of Envoy Medical?

Envoy Medical is trading at $0.69 per share.

What is the 52-week range for Envoy Medical?

Over the past 52 weeks, Envoy Medical has traded between $0.36 and $1.89.

How much debt does Envoy Medical have?

As of the most recent reporting period, Envoy Medical reported total debt of $889.00K.

How much cash does Envoy Medical have on hand?

Envoy Medical reported $25.25M in cash and cash equivalents in its most recent financial results.

What is Envoy Medical’s dividend yield?

Envoy Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services